Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT03123783

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma

Sponsor: Apexigen America, Inc.

Conditions Cancer Melanoma Metastatic Melanoma Neoplasm of Lung Non Small Cell Lung Cancer Metastatic

Interventions APX005M Nivolumab

Updated 23 times since 2017 Last updated: Dec 21, 2023 Started: Jul 10, 2017 Primary completion: Nov 16, 2020 Completion: Nov 16, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Cancer and Melanoma and is currently completed. Apexigen America, Inc. leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2023 — Jan 2024 [monthly]

Completed PHASE1_PHASE2

▶ Show 18 earlier versions

Apr 2022 — Jun 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2022 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Dec 2021 — Jan 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2021 — Dec 2021 [monthly]

Completed PHASE1_PHASE2

Status: Terminated → Completed
Jan 2021 — Jun 2021 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Aug 2020 — Oct 2020 [monthly]

Recruiting PHASE1_PHASE2
May 2020 — Aug 2020 [monthly]

Recruiting PHASE1_PHASE2
Jun 2019 — May 2020 [monthly]

Recruiting PHASE1_PHASE2
Apr 2019 — Jun 2019 [monthly]

Recruiting PHASE1_PHASE2
Dec 2018 — Apr 2019 [monthly]

Recruiting PHASE1_PHASE2
Oct 2018 — Dec 2018 [monthly]

Recruiting PHASE1_PHASE2
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Oct 2017 — May 2018 [monthly]

Recruiting PHASE1_PHASE2
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE1_PHASE2
Jun 2017 — Aug 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Apexigen America, Inc.
Bristol-Myers Squibb

Data source: Apexigen America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Barcelona, Spain , Cleveland, United States , Duarte, United States , Las Palmas de Gran Canaria, Spain , Lugo, Spain , Madrid, Spain , Málaga, Spain , Nashville, United States , New Haven, United States and 8 more locations